Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Cell Metab. 2019 Sep 5;30(4):706–719.e6. doi: 10.1016/j.cmet.2019.08.005

Figure 3: Partial, not complete reduction of circulating leptin, protects mice from obesity.

Figure 3:

ALepKO and littermate control mice were placed on HFD supplemented with two different amounts of Doxycycline (DOX) (600mg/kg (DOX600) and 10mg/kg (DOX10)). Body weights, circulating leptin levels, OGTTs, ITTs and histological analysis were performed. (A) Body weight gain of ALepKO (n = 6) and littermate controls (n = 7) on DOX600; (B) body weight gain ALepKO (n = 7) and littermate controls (n = 7) on DOX10; (C) Circulating leptin levels per total fat mass of ALepKO (n = 7) and littermate controls (n = 6) before and after DOX 600; (D) Circulating leptin levels per total fat mass of ALepKO (n = 9) and littermate controls (n = 8) on DOX10; (E) OGTT on ALepKO (n = 8) and littermate controls(n = 6) on DOX600; (F) OGTTs on ALepKO (n = 6) and littermate controls (n = 11) on DOX10; (G) ITTs on ALepKO (n = 6) and littermate controls (n = 6) DOX600; (H) ITTs on ALepKO (n = 6) and littermate controls (n = 8) on DOX 10; (I) Brown adipose tissue histology on DOX600; (J) Brown adipose tissue histology on DOX10; (K) Oxygen consumption (VO2) of ALepKO (n = 6) and littermate controls (n = 6) on DOX10 in metabolic cages; (L) Locomotor activity of ALepKO mice (n = 6) and littermate controls (n = 6) on DOX10 during the dark period, daytime and across the entire 24hr period.

(Data are given as mean ± SEM. Error bars indicate SEM. *p < 0.05; **p < 0.01; ***p < 0.001).